Cytopathology · 2016 · 28 citations · 24 references
MedicinePathologyUrologyCellular PathologyCytopathologyGenitourinary OncologyBladder CancerMolecular CytopathologyTumor CytopathologyUrinary CytologyUrologic Cancer DiagnosisUrothelial CarcinomaAtypical CellsAtypical Urothelial CellsBladder Cancer CytologyImmunocytochemistry In Urine CytologyKi-67 ImmunostainingUpper Urinary Tract CytologyUrine-based Cancer DetectionUrothelial Carcinoma Cytology
Objective The presence of atypical cells in urine cytology is unsatisfactory for both cytologists and clinicians. The objective of this study was to test whether p53 and Ki‐67 immunostaining could improve urothelial carcinoma ( UC ) detection on urinary cytology. Methods A total of 196 urine samples were analysed, 142 from the bladder, 41 from the upper tract and 13 from ileal bladder replacement. Cytology results were expressed as normal (N) ( n = 81), atypia cannot exclude low‐grade UC ( ALG ) ( n = 25), suspicious for high‐grade UC ( SHG ) ( n = 39) and high‐grade UC ( HG ) ( n = 51). Actual diagnoses were confirmed by histopathological analysis, cystoscopic examination or follow‐up for at least 1 year. Immunocytochemistry performed on CytoSpin ™ slides allowed the determination of the percentage of positive cells with p53 and Ki‐67. Results The median percentage values [first to third quartile] of p53 and Ki‐67 were 0 [0–5] and 0 [0–1] for N cytology, 5 [0–40] and 2 [1–10] for ALG , 10 [0–30] and 6 [3–25] for SHG , and 30 [10–80] and 20 [10–30] for HG , respectively. Statistically higher values were observed for both tests ( P < 0.001) in positive cytologies ( ALG , SHG and HG ). The optimal cut‐offs were 5% for p53 and 3% for Ki‐67. The sensitivity and specificity for the detection of all UC were 86.4% and 76.7% for cytology alone, 81.3% and 93.2% for cytology and p53, 75.7% and 88% for cytology and Ki‐67, and 68.9% and 97.5% for cytology, p53 and Ki‐67, respectively. Conclusion Using p53 and/or Ki‐67 in addition to cytology increases the specificity without penalising the sensitivity.
24
Accumulation of Nuclear p53 and Tumor Progression in Bladder Cancer
David Esrig, Donald A. Elmajian, Susan Groshen et al. · New England Journal of Medicine · 1994 · 808 citations · Full text
European Guidelines on Upper Tract Urothelial Carcinomas: 2013 Update
Morgan Rouprêt, Marko Babjuk, Éva Compérat et al. · European Urology · 2013 · 451 citations
Bas W.G. van Rhijn, André N. Vis, Theodorus van der Kwast et al. · Journal of Clinical Oncology · 2003 · 321 citations